# 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

> **NCT01590459** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 359 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** VX-509
- **DRUG:** VX-509 matching placebo

## Key facts

- **NCT ID:** NCT01590459
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590459, "24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01590459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*